Method of using oral lipase inhibitors to reduce plasma ghrelin and to prevent weight regain

Abstract

The present invention comprises a method of reducing ghrelin levels in a human body for weight reduction and to permanently reduce appetite and eliminate weight regain by the step of orally ingesting tetrahydrolipstatin—THL (Orlistat) on a regular basis for a period of at least one to two years.

1 . A method of depressing serum ghrelin levels in a body by the step of:
 ingesting daily a compound of tetrahydrolipstatin (THL) for a period of at least two years.   
     
     
         2 . A method of atrophying ghrelin levels in a human body for weight reduction and to permanently reduce appetite and eliminate weight regain by the step of:
 orally ingesting an admixture of tetrahydrolipstatin-THL on a regular basis for a period of at least eighteen months.   
     
     
         3 . The method of  claim 2 , wherein said tetrahydrolipstatin comprises orlistat. 
     
     
         4 . A method of reducing post Orlistat therapy ghrelin production and eliminating associated weight regain by:
 maintaining an Orlistat therapy program for a period of at least two years.   
     
     
         5 . The method as recited in  claim 4 , wherein said Orlistat is ingested daily during or immediately subsequent to a meal.